177 - Policy Changes Shaping the Future (S12E12)

Welcome to the deep dive. We're here to make
sense of the complex world around us. And today,
we're tackling something really fundamental to
medicine, but maybe a bit behind the scenes.
Policy changes and regulatory reforms in drug
development. Yeah, it sounds dry, maybe, but
it has this huge impact. It really shapes how
new treatments are developed, how they get approved.
Just like the rule book is constantly being updated,
right? Yeah. We've looked at a whole range of
sources, the really foundational stuff, like
the Code of Federal Regulations. The CFR, yep.
All the way to the very practical, hands -on
research you see in organic process research
and development, OPRND. Right, that real -world...
chemistry perspective. So our mission today is
really to try and get a clearer view of what
shifts might be coming, what are the current
debates, the potential changes, and how is the
industry actually preparing. Exactly, because
these regulations, they don't exist in a vacuum.
They have to adapt. Science changes, technology
changes. We learn things. We learn things, precisely.
So understanding where things might be headed
isn't just an academic exercise. It's about the
future of health care innovation itself. And
using those real examples, especially from places
like OPR &D, helps make it tangible. OK, so before
we jump into the future, maybe we should quickly
sketch out the present. What's the basic regulatory
landscape look like right now? Well, The core
idea, whether it's the FDA in the US or international
efforts like ICH, is always about safety. Efficacy,
does it work? And critically, manufacturing quality.
Right. And when you talk manufacturing, Title
21 of the Code of Federal Regulations is, well,
people often call it the Bible for that area.
The Bible, okay. And within that, I hear a lot
about GMP. Ah, GMP. Good manufacturing practices,
absolutely fundamental. It's all about setting
up processes to prevent... errors and ensure
consistency and quality. So kind of like the
master recipe and instructions for making a drug
safely every single time. That's a great way
to put it and a huge part. of GMP, maybe the
biggest part is documentation. You have to write
everything down. Pretty much. The certified pharmaceutical
GMP professional handbook really drives this
home. It's how you prove you followed the rules,
how regulators can trace everything if needed.
But beyond just avoiding mistakes, there's this
push towards something called quality by design,
QBD. QBD, yeah, that term keeps popping up. Yeah.
What's the shift there? What does it really mean?
So instead of the old way, which was maybe make
a batch. Test it at the end. Hope it passes.
Fingers crossed. Huh, maybe a bit. QBD flips
that. It's about building the quality into the
process from the very beginning. You identify
what really matters for the drug. the critical
quality attributes, and then you design your
manufacturing process, including defining a design
space, which is like the acceptable operating
window, to ensure you hit those attributes consistently.
Comprehensive quality by design explains this
really well, and agencies like the FDA, they're
really encouraging this proactive approach. Oh,
okay, so it's like understanding exactly how
oven temperature, mixing time, ingredient ratios,
all guarantee a perfect cake, rather than just
tasting it afterwards. Exactly, it's process
understanding. What about unwanted stuff getting
into the drug? Impurities. Oh, definitely. Managing
impurities is another huge piece. Guidelines
like ICH, Q3BR, and resources like safety evaluation
of pharmaceuticals and medical devices, they
provide the framework. You need to figure out
where impurities might come from, understand
the risks, and set strict limits. Limits based
on safety, presumably. Absolutely. And for certain
types, like DNA reactive impurities, things that
could potentially cause genetic damage, the FDA
has even more specific guidance on how low those
levels need to be and how you prove it. Got it.
So that's the baseline. Now let's look ahead.
What are some of these potential policy changes
or reforms that people are talking about? Where
might the rules shift? Well, there are a few
areas getting attention. One is around dietary
supplements, specifically those with new dietary
ingredients. OK. Right now, under 21 CFR 190
.6, companies need to notify the FDA 75 days
before marketing, providing safety data. There's
ongoing discussion about whether those requirements
need to be strengthened. To strengthen how? Like
demanding more data upfront? Potentially, yes.
To give greater assurance about safety before
something hits the shelves. Another area is how
data from clinical trials conducted outside the
US is used. Foreign clinical data. The FDA does
accept it for IND applications and approvals.
That's in 21 CFR 312. But the sponsors have to
show the studies followed good clinical practice,
GCP. The standards might evolve on exactly what
evidence is needed to prove that. Right. You
want to ensure the science and ethics hold up.
wherever the trial was done. Makes sense. What
else? The orphan drug designation that's under
21 CFR 316. This gives incentives like market
exclusivity for developing drugs for rare diseases.
Really important area. Hugely important. But
there are always discussions around, well, what
qualifies as rare? How long should exclusivity
last? Could the designation be revoked under
certain conditions? Those definitions and terms
could see adjustments. I can imagine that's a
tricky balance encouraging development without
creating you know, access issues later on. It's
a constant balancing act. And finally, something
maybe less headline grabbing, but still vital.
The rules around electronic records and signatures.
21 CFR Part 11. As tech evolves, how companies
manage data digitally, ensure its integrity,
prove compliance, those rules likely need updating
too. OK, so if some or all of these changes happen,
what's the real world effect? How does this actually
impact the process of getting a new drug from
the lab to the patient? Well, the most immediate
thing people think about is time and money. Drug
development is already incredibly long and expensive.
The clinical trials handbook lays that out pretty
starkly. If new regulations demand, say, larger
trials, more complex analyses, or more extensive
pre -market data, like we discussed for supplements,
that inevitably adds to the timelines and the
costs. So potentially making it even harder,
or at least more resource intensive, to innovate.
That's definitely a concern, yes. Another impact
could be on sourcing starting materials for manufacturing.
The CMC transcripts from season 11 really emphasize
risk assessment across the whole supply chain.
If regulations tighten, companies might need
to do much more rigorous auditing of their suppliers,
or demand stricter quality specs for raw material.
OK, adding layers of complexity to manufacturing.
It could, yes. The aim would be enhanced safety
and reliability, but it adds work. And then there's
clinical trial design itself. We might see changes
affecting, for instance, when you can recalculate
sample sizes mid -trial. Sample size re -estimation,
yeah. As mentioned in the clinical trials handbook.
book, or the further adoption and regulation
of adaptive trial designs. These are trials that
can be modified based on incoming data. Adaptive
designs. They sound more efficient, potentially.
They can be, absolutely. Books like Clinical
Trial Design, Bayesian, and Frequentist Adaptive
Methods explore this. But they also require careful
planning and regulatory buy -in. They're more
complex to manage. Right. So more sophisticated,
but maybe more regulatory scrutiny, too. Precisely.
And you might also see regulators putting more
emphasis on certain drug properties earlier on.
Think about AD meat properties, absorption, distribution,
metabolism, excretion. I've covered back in seasons
two and three. Exactly. How a drug behaves in
the body. We might see stricter requirements
for characterizing those properties during lead
optimization or preclinical work. And of course,
the FDA and similar agencies set the bar for
all safety testing and oversee the phases of
clinical trials, as we know. from seasons three
and four. Any tweak to their guidance directly
changes how studies are conducted. It really
sounds like companies need to be incredibly agile,
constantly scanning the horizon for these shifts.
So how are they responding strategically? Are
there good examples? Maybe pulling from that
OPR &D literature you mentioned. Oh, absolutely.
Companies are definitely not sitting still. One
major trend is the increased use of process analytical
technology, PIT. Yeah, this involves using sensors
and real -time monitoring during the manufacturing
process itself. A 2021 OPR &D paper by Garcia
and colleagues showed a great case study. It
helps ensure consistency, control quality better,
and frankly, makes it easier to demonstrate compliance
with evolving regulations. So using tech to get
a much tighter grip on the actual making of the
drug. Exactly. Another big area, driven partly
by efficiency and cost, but also environmental
concerns, is continuous flow synthesis. There
was a really neat OPR &D paper in 2019 from CAPI's
group. They did a large -scale flow synthesis
for a key part of the antidepressant peroxetine
using a solvent -free heterogeneous catalyst.
And using catalysts effectively in flow systems
like this can overcome some traditional scale
-up challenges. It points towards more efficient,
possibly greener manufacturing, which definitely
aligns with where regulations might push things.
That's fascinating. Optimizing the chemistry
itself is a response. And OPRND is just packed
with examples of that kind of optimization. Improving
yields, reducing impurities. You see papers detailing
the synthesis of specific building blocks, like
one from 2021 on a dioxy spiro compound, or another
from 2020 on making an azetidine, or optimizing
specific reactions like an amidation in 2020.
So really getting into the nitty -gritty chemical
details. Absolutely, because nailing those reaction
conditions solvent, temperature, amounts of stuff
you add is critical for getting a pure product
reliably, especially when you scale up. That's
often where you hit roadblocks like solubility
issues, and that's where this detailed process
chemistry becomes vital for meeting regulatory
specs. It's deep level problem solving. It really
is. And related to that, we're seeing new synthetic
methods in OPR &D that could help navigate potential
regulatory hurdles around, say, problematic byproducts
or environmental impact. Think about using water
as a solvent for major reactions like HEC and
Suzuki couplings. There was work on that reported
in OPR &D in 2022. Using water instead of traditional
organic solvents. That's a big shift. A huge
shift, potentially offering major safety and
sustainability advantages. And that's something
regulators are increasingly interested in. Then
there's the physical form of the drug crystallization
and polymorph control. The actual solid structure.
Yes. How the drug crystallizes affects its properties.
A 2017 OPR &D paper by Kumar et al. gets into
the strategies. And even seemingly small things,
like how you stir the mixture during crystallization
scale up, can impact which polymorph you get,
as polymorphism in the pharmaceutical industry
highlights. Regulators care a lot about consistent
physical form. So many. factors to control. It's
incredibly complex. And one last thing to mention
is the rise of AI and machine learning. The Era
of Artificial Intelligence book talks about its
growing role. AI could potentially help predict
clinical trial outcomes, identify safety signals
earlier, or optimize manufacturing processes
to better align with shifting regulatory expectations.
It's a tool that could help manage this evolving
landscape. Wow. It really does feel like we're
at this intersection point, scientific advancement
and regulatory evolution driving I think that's
exactly right. Drug development is inherently
dynamic. And understanding these potential policy
and regulatory shifts is just, well, it's essential
for everyone involved, from researchers to manufacturers
to regulators themselves. It's about ensuring
we can keep bringing forward safe, effective,
and innovative medicines. So wrapping up this
deep dive, the big question maybe left hanging
is. Yeah. How will all these potential changes,
this evolving landscape, ultimately play out
for patients? You know, in terms of access, affordability,
it feels like this constant tension, doesn't
it? Balancing rigorous oversight with encouraging
innovation and ensuring that the treatments developed
actually reach the people who need them. That's
the core challenge, always. It's definitely something
to keep watching as these policies continue to
take shape. Thanks so much for breaking this
down for us today. My pleasure. It's a fascinating
area. And thank you for joining us on this Deep
Dive. We'll be back soon with another exploration
beneath the surface.